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CHAPTER 1. GENERAL INTRODUCTION 
THESIS ORGANIZATION 
This thesis describes the genotypic and phenotypic characterization of the equine 
infectious anemia virus (EIA V) regulatory protein, Rev. This thesis includes further study of 
genotypic variation observed within two subpopulations of a Rev quasispecies identified 
within an EIAV-infected horse (5, 8), and the effect of these mutations on Rev phenotype. 
The thesis also includes the analysis of another EIA V-infected horse, and the identification of 
subpopulations of Rev within this pony. The thesis is in manuscript format, consistent with 
the Journal of Virology, and is divided into four chapters, two of which are presented as 
journal articles. Chapter 1 is a general introduction into the evolutionary mechanisms of 
viral persistence, with an emphasis on lentiviruses. It includes background information on 
the lentivirus EIAV, and the use ofEIA Vas a model of lentiviral persistence. This chapter 
also includes specific background information of the characterization of an EIAV-infected 
horse, pony 524, and the analysis of Rev variants observed throughout the clinical disease 
course which provide the foundation for the work presented in this thesis (8). Chapter 2 is a 
manuscript to be submitted to the Journal of Virology that describes the characterization of 
mutations fixed into the viral population of the previously described EIAV infection of pony 
524, and the effect of these mutations on Rev phenotype. Sijun Liu helped design the 
cloning strategy, and both he and Susan Vleck helped prepare the mutant Rev clones used in 
this study. Chapter 3 describes my work on the characterization of the Rev quasispecies in 
pony 625, and the identification of two subpopulations which differed in phenotype. The 
Rev variants were compiled by Robert Thompson and myself, and the experimental 
infection, collection of serum samples and the recording of the clinical profile of this pony 
was performed by our collaborator, J. Lindsay Oaks of Washington State University. 
Chapter 3 is extracted in part from a manuscript previously published in Journal of Virology, 
which characterized the Rev quasispecies of afore mentioned pony 524, as well as another 
EIAV-infected horse, pony 625 (8). Chapter 4 is a general conclusion of these studies, and 
their impact on how the evolution of viral quasispecies may contribute to lentiviral 
persistence. 
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VIRAL EVOLUTION 
Evolution, the process of changing the genetic properties of a population, is 
influenced by several factors, including mutation, genetic drift, selection, migration, and 
recombination. The evolution of RNA viruses is shaped by these same evolutionary forces, 
and inherent characteristics of these viruses make them well suited to the study of the 
mechanisms of evolution. Understanding these mechanisms is key to our ability to contain, 
control, and eradicate viruses, as well as providing insight into the evolution of more 
complex organisms. 
Mechanisms of viral evolution. RNA viruses have large population size, high 
replication rate, high replication error, and small genome size. These characteristics allow 
both the study of evolution in real time, and the in depth analysis of how these mechanisms 
of evolution confer adaptability to a species in a changing environment. Two theoretical 
approaches, deterministic and stochastic, have been used to model viral evolution. 
Deterministic approaches, including natural selection and quasispecies theory, assume a large 
population size, on which stochastic processes would have little effect (79). Darwin's theory 
of natural selection predicts that genotypes with greater fitness, measured as ability to survive 
and reproduce, increase in frequency over time. Natural selection is more efficient in large 
populations, and studies have shown that RNA viruses, with their large population size, 
reflect the appearance of new mutations with greater fitness over time, which can out-
compete older variants (19). The viral polymerases encoded by RNA viruses lack 
proofreading capabilities resulting in the highest mutation rates of all know organisms, 
approximately one mutation per genome replication (29, 58). The mutation rates of RNA 
viruses exist near the error threshold, the point at which the number of deleterious mutations 
introduced in each replication cycle is so great that the most fit viral variants are unable to 
reproduce, and the population size decreases to extinction (66). This high mutation rate, 
coupled with the high replication rate of RNA viruses and small genome size, means that 
theoretically, every point mutation in the virus could be produced daily (3). These viral 
populations would be able to produce many beneficial mutations, providing a means to adapt 
to a changing environment in a short period of time (66). 
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Natural selection acting on this multitude of mutational variants, however, does not 
fully explain the whole of viral evolution. Stochastic processes, such as genetic drift, 
contribute to viral evolution when environmental factors or intrinsic properties of the 
population lead to a smaller effective population size, that is much smaller than the number 
of infected cells (79). Variation in replication rate, generation time of infected cells, the 
number of infected cells, and population bottlenecks all contribute to an effective population 
size (66). Recombination is another key factor in viral evolution. Some RNA viruses have 
recombination rates which exceed their mutation rates (77). Recombination allows the virus 
to evolve higher fitness mutants faster than mutation alone, and may allow purging of 
deleterious mutations (66). Simulations, however, have predicted frequent recombination, in 
viruses with mutation rates near the error threshold, is more likely to have deleterious effects 
on fitness (3). Migration of viruses is another factor contributing to viral evolution, whose 
effects are not yet well characterized. This factor is complicated because it exists on both 
macroscopic and microscopic levels. Migration at a macroscopic level can be observed 
among hosts within a population, between populations of the same species, and across 
populations of different species. Migration at the microscopic level exists within a single 
host, and encompasses viral transport across different tissues and cell types (66). Whether at 
a macroscopic or microscopic level, migration contributes to the overall variation of a viral 
population. 
Limits on viral variation in vivo. Studies suggest that RNA viruses have a narrow 
tolerance to accumulate mutations and still maintain necessary function and structure (27, 
28). Beneficial mutations are predicted to be ~ 1000 fold less common than neutral and 
deleterious mutations (83). Maximum likelihood models have shown that positive selection 
acts on a small number of sites, while the majority of positions are under neutral or purifying 
selection (68). This is illustrated in vivo in multiple RNA viruses, where observed amino 
acid changes are similar across hosts within a species, as well as across time (11, 16, 7 4, 78, 
85). 
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QUASISPECIES 
Quasispecies theory. Quasispecies theory was developed by Eigen and Schuster to 
better model the evolution of primitive systems. The quasispecies is defined as the 
distribution of a mutant swarm around the master sequence (31 ). That is, a large population 
composed of the most fit (master) sequence, surrounded by a swarm of mutants, the result of 
erroneous copying of the master sequence. Quasispecies theory differs from previous models 
in that natural selection acts on the entire quasispecies, not on individual members of the 
population. The master sequence can be produced through erroneous replication of 
members of the mutant swarm, and likewise, mutations can occur in the master sequence to 
place it in the mutant swarm. As a result of this, the most fit variant within a quasispecies 
can be out-competed by less fit, slower replicating, variants if the less fit variants have a high 
probability of being created by erroneous replication of closely related variants (66). 
Viral quasispecies. Inherent properties of RNA viruses, such as high replication rate 
resulting in a large population size, and high error rates associated with replication, allow 
them to represent the biological entities of quasispecies theory. The applicability of 
quasispecies theory on viral populations in vivo, however, has not been clearly established. 
Though often cited as proof of the existence of a quasispecies, high genetic variation, 
mutation rates near the error threshold, and even the observation of lower fitness genotypes 
out-competing higher fitness genotypes, can be explained by other evolutionary mechanisms 
(66). To provide evidence supporting the existence of RNA viruses as quasispecies one must 
show natural selection acts upon the entire population of viral genomes, not just an individual 
genome. 
Also, quasispecies theory does not account for several in vivo observations. 
Stochastic effects contributing to evolution have been observed within viral quasispecies. 
For example, it has been shown that effective populations size exists in vivo, the result of 
transmission bottlenecks, and immune pressure (69, 79, 30, 66). Decreases in the actual 
population size of RNA viruses, resulting from genetic bottlenecks, have been show to result 
in less fit variants becoming dominant through a ratchet effect of decreasing fitness known as 
Muller's ratchet (30). 
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The viral quasispecies is an ever changing, complex system that can rapidly respond 
to changes within its environment (26). Wright's shifting balance theory provides a model in 
which both deterministic and stochastic mechanisms act to enable populations to move 
toward a fitness peak (94). Changes in viral fitness can be described as the movement of 
viral genomes across a rugged fitness landscape with multiple peaks and valleys (28). 
Natural selection directs this movement to the top of fitness peaks, which correspond to 
different paths of viral evolution to achieve higher fitness. A population near the bottom of a 
fitness peak will more readily gain fitness, while populations near the top of the fitness peak 
are more likely to lose fitness, due to deleterious mutations (69). Wright's theory suggests 
that drift allows the population to explore the fitness surface, to shift onto new fitness peaks, 
and then selection would act to move the population to the top of the peak. In this manner, 
both stochastic and deterministic processes may act in concert to confer greater adaptability 
to changes in the environment. 
Subpopulations of viral quasispecies. Recent studies have provided support for 
multiple viral populations, or subpopulations of the quasispecies, occupying different fitness 
peaks (2, 15, 74, 5, 8). This would allow the virus as a whole to adapt much more quickly in 
the face of environmental change. A subpopulation near the new fitness peak would more 
rapidly fix advantageous mutations, without having to traverse a valley or saddle between 
fitness peaks associated with deleterious mutations. Moreover, these subpopulations are 
shown to evolve independently of one another, and exhibit distinct phenotypic differences 
(13, 15). However, there is evidence that two subpopulations, each exhibiting increasing 
fitness (an example of the Red Queen hypothesis), will eventually out-compete each other 
(18). This follows the Competitive Exclusion principle, in which one species will eventually 
out-compete another, unless there is a biological niche which allows the continued existence 
of the out-competed species. The environment is constantly changing, however, and as viral 
subpopulations continue to vie for dominance subpopulations out-competed in earlier 
environments may reappear, and become dominant (18). 
Compartmentalization and viral memory. The host of a viral infection provides 
multiple niche environments for viral subpopulations to occupy. Spatial heterogeneity has 
been observed between different cell types of a host, within an infected organ, and even in 
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subcellular compartments (33, 81). This compartmentalization provides opportunity for the 
virus to achieve much greater fitness over time, not only through immediate quasispecies 
shifts, as mentioned earlier, but also in terms of viral memory. Memory in viral quasispecies 
is defined as viral genomes hidden within the mutant spectra which represent a molecular 
history of the evolution of the viral population (80). Viral memory results in fitness increases 
comparable to the increase undergone by the entire viral quasispecies (4). This memory can 
be the result of both replicative and cellular mechanisms. RNA viruses may infect cells 
which then remain latent for years (7, 17, 38). This allows for the continued existence of a 
fitness phenotype over decades without the variant having to persist through viral replication 
(7). Viruses may also employ phenotypic mixing and hiding, a form of complementation, as 
a means to maintain viral genomes (92). In this case, mutant genomes packaged into wild 
type surface proteins would be able to hide their mutant genotype behind the wild type 
phenotype of the surface proteins. Surface proteins of a virus are key in determining host 
and cell specificity. Also, infection of a single cell by multiple virions would allow 
recombination and reassortment of different viral subpopulations. This would allow 
phenotypic mixing and hiding not only between a mutant encapsidated by its parental 
proteins, but also between two separate viral strains (92). Maintaining memory genomes, 
even if they are less fit than other members of the mutant spectra, ultimately provides greater 
adaptability to the viral quasispecies over time. 
RETROVIRUSES 
Common characteristics of retroviruses. Retroviruses are single stranded RNA 
viruses, which encapsidate two copies of their positive sense RNA genomes. They are 
unique, in that the virus encodes both a reverse transcriptase (RT) and an integrase (IN), to 
form a DNA copy of its genome which is then integrated into the host genome. The 
integrated viral genome, termed the provirus, provides the template for viral replication 
within the host. Retroviruses have a high rate of replication, producing up to 109 new viral 
RNAs per day (88). Reverse transcription is a critical step for the retrovirus, and RT, with its 
characteristic DNA polymerase having specificity for both RNA and DNA templates, allows 
the replication of the viral genome from the positive stranded RNA genome to a double 
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stranded DNA genome through a RNA/DNA intermediate. The RT lacks a 3' exonuclease, 
rendering it unable to proofread the reverse transcription of the viral genome, resulting in 
high error rate ofreplication, on the order ofl 0·4 to 10·5 (57). Also, the process ofreverse 
transcription requires two strand transfer events to create the full length proviral genome. 
The retroviral RT has developed nonprocessivity, as well as low template affinity, to 
accommodate the strand transfers, which may occur on one copy of the viral RNA genome, 
or be recombinant between the two copies of the viral genome (88). Strand transfer may also 
occur throughout replication, not just at the two required transfers. This results in both high 
error rate, as well as high recombination rate. Coupled with the high replication rate of 
retroviruses, this results in a mutant swarm of variants, a retroviral quasi species (27, 43). 
Lentiviruses. Lentiviruses are one of seven genera of the family of retroviruses, 
associated with chronic disease in mammalian hosts. Lentiviral genomes are complex, 
encoding regulatory and accessory proteins not found in other retroviruses. The high genetic 
variation of these lentiviral quasispecies contributes to lentivirus persistence (45, 48, 70, 73). 
The human immunodeficiency virus type 1 (HIV-1) is the best characterized lentivirus, due 
to its profound impact on human health worldwide. The HIV-1 quasispecies shows a great 
amount of variation from the time of initial infection until the development of acute 
immunodeficiency syndrome (AIDS). Multiple studies have shown the initial diversity of a 
population after infection to be low, suggesting a transmission bottleneck (25, 39, 84, 93). 
Over time the quasispecies becomes more diverse and more divergent from the founder 
population (75, 84). The rate of disease progression is influenced by many factors, including 
viral load, the founder population, as well as the host (14, 71, 84). Different viral 
quasispecies have been associated with different rates of progression, as well (55, 76, 84, 91). 
Subpopulations of lentiviral quasispecies. Recent studies have also identified 
minor populations of viral quasispecies which act as a reservoir of diversity, resistance, and 
persistence, or viral memory. Minor populations with drug resistance were shown to evolve 
independently of the dominant population, and were able to persist over time, despite 
decreases in replication fitness, and become dominant ( 11, 15). Infection of immune cells, 
which may remain latent for years, has been documented, and ancestral viral sequences 
observed up to ten years later with no evidence of any intermediate viral variants (7, 38). 
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Infection of other tissues, such as the brain, gut-associated lymphoid tissue, thymus, bone 
marrow, spleen, and genital tract may also contribute to rapid genotypic and phenotypic 
shifts observed within a quasispecies (12, 17). Viral reservoirs would allow the virus to 
quickly adapt to drug treatment and environmental change, while compartmentalization may 
also allow the virus to replicate in regions unaffected by drug therapy. Multiple studies have 
documented the rapid rebound of virus after drug therapy is discontinued (17, 23, 50, 60). 
The inherent genetic variation of HIV-1, coexisting, independently evolving, subpopulations, 
and memory reservoirs of ancestral sequences all contribute to our inability to contain and 
control this virus, let alone to eradicate or provide immunity against it. Continual low level 
viral replication is observed even in patients on strict drug therapy (34, 3 7, 49). 
Lentiviral genes under selection. Positive selection, acting on a small number of 
sites, has been observed within all nine HIV-1 genes (24, 95). Positive selection of the env 
gene of HIV-1 has shown a nonuniform distribution of positively selected sites, relating to 
cell tropism, antibody binding, and syncytium inducing phenotype (68, 78). Changes at these 
sites were found in multiple hosts, suggesting selection to escape the host immune response 
drives the variation observed in this gene. Also, the number of sites under positive selection 
was a marker for the rate of disease progression. Long term progressors exhibited positive 
selection at more sites and over a longer period of time than short term progressors (78). 
This is interpreted as evidence for a broad persistent immune defense conferring longer 
survival time with HIV-1 infection. Another study of the positively selected sites in env 
found similar changes across three divergent HIV-1 lineages (thought to be the result of three 
separate cross-species transmissions) and to be associated with N-glycosylation sites (16). 
Mutations conferring drug resistance in the protease and RT genes also persist over time, and 
occur at a limited number of sites (11 ). Positively selected sites have also been identified in 
regulatory and accessory proteins, such as Rev, Tat, Nef, and Vif, though their effect on 
phenotype and fitness is unknown (24). 
EQUINE INFECTIOUS ANEMIA VIRUS (EIA V) 
EIA V as a model of lentiviral persistence. Equine infectious anemia virus (EIA V) 
is member of the lentivirus genus, infecting equids worldwide. EIAV is similar to other 
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lentiviruses, such as HIV-1, in its genome organization, tropism for cells of the 
monocyte/macrophage lineage, and a lifelong persistent infection. EIA V infection causes a 
rapid clinical disease characterized by clearly defined stages of disease: acute, chronic, and 
inapparent ( 41, 4 7, 52, 62). Upon infection, most horses undergo acute disease, 
characterized by high levels of viral replication, fever, and thrombocytopenia. The resolution 
of the acute stage coincides with the appearance of virus specific cytotoxic T lymphocytes 
and a decrease in levels of plasma viremia ( 40, 62). Recurrent cycles of viremia associated 
with fever, thrombocytopenia, and wasting occur throughout the first year after initial 
infection. These chronic episodes abate in both frequency and severity over time. Onset of 
the inapparent stage of disease is associated with maturation of the cellular and humoral 
immune system (8, 20, 40, 65, 82). EIA V is unique among lentiviruses, however, in that 
most infected animals effectively control viral replication to progress past the chronic stage 
of disease into the asymptomatic stage. These animals are inapparent carriers, infected for 
life. This makes EIA V an excellent system to study genetic variation of lentiviruses and how 
it contributes to lentiviral persistence and pathogenesis. Understanding the natural 
mechanisms of EIA V control would enhance strategies to treat or vaccinate against HIV 
infection. 
EIA V variation. EIA V (Fig. 1) exhibits great genetic variation, and the error rate of 
RT has been shown to be as high as HIV-1 ( 6). The quasispecies nature of EIA V has been 
demonstrated for the genes env and rev, as well as the untranslated long terminal repeats 
(LTR) (1, 8, 54, 61, 86). Mutations within env have been shown to contribute to the 
emergence of neutralization-escape variants (54, 87). Variation in the LTR is associated with 
in vitro adaptation to non-natural target cells, however, its role in vivo is not clear (53). 
Variation in EIA V Rev alters the biological phenotype of Rev mediated nuclear export 
activity (8, 9). Interestingly, a recent study has identified several cytotoxic T lymphocytes 
(CTL) epitopes within EIA V Rev (64), suggesting there may be direct immune pressure on 
EIA V Rev. Mutations in HIV-1 Rev have been shown to alter sensitivity to CTL killing, by 
down regulating the expression of structural genes (10), contributing to immune evasion. 
Although the role of Rev in long term viral persistence is not fully understood, the necessity 
of Rev for viral replication, its ability to contribute to immune evasion, as well as being a 
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target of immune selection, suggests that genetic variation in Rev contributes to EIA V 
persistence. 
Rev Function. Rev is a nucleocytoplasmic shuttling protein absolutely critical to 
viral replication, produced from a completely spliced bicistronic proviral mRNA. Rev 
exports partially spliced and unspliced mRNA out of the nucleus into the cytoplasm for 
translation of the structural proteins necessary for viral replication, as well as full length viral 
genomes. The mechanism of Rev is best described for HIV-1. To successfully export 
partially spliced and unspliced viral mRNAs, Rev must return to the nucleus, bind the viral 
mRNA at a region termed the Rev responsive element (RRE) (21, 97), multimerize (72, 96), 
and then export the RNA-protein complex into the cytoplasm via the CRMl/exportinl 
pathway (22, 32, 35). Each step in this pathway is mediated by discrete functional domains 
within Rev. These functional domains have been defined via multiple methods, including 
mutagenesis, chemical interference, and in vitro RNA selection. HIV-1 Rev contains an N-
terminal arginine-rich region (ARM) necessary for RNA binding, which also includes the 
nuclear localization signal (NLS) (44, 56, 63), and a C-terminal leucine-rich nuclear export 
signal (NES) (32, 35, 46). The functional motifs within these domains are not unique to 
viruses, nor are they identical across all lentiviruses. The 17 amino acid ARM of HIV-1 has 
been shown to be important to RNA binding (51, 89). Similar ARMs have been found in 
bacterial anti-terminators, ribosomal proteins, and HIV Tat. The ARM of HIV-1 is thought 
to function by forming an alpha-helix which binds the major groove of the viral RNA. An 
arginine rich peptide from cowpea chloritic mottle virus coat protein, thought to be involved 
in RNA packaging, also displays a helical form (90). 
EIA V Rev is functionally homologous to HIV-1, though the domain layout is quite 
different (42, 67, 36, 59). The functional domains of EIAV Rev all lay within the second 
exon of Rev, whereas, in HIV Rev, the functional domains are found in both exons. 
Likewise, genetic variation of EIAV Rev is observed in the second exon of Rev, while exon 
1 is highly conserved (5). EIAV contains an N-terminal NES, functionally homologous to 
HIV-1, and a C-terminal NLS, distinct from a central RNA binding domain (36, 59, 67). 
Deletion mutant studies have identified a central region that is essential to Rev function, as 
well as a small region which is non-essential to Rev function (42). 
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REV VARIATION AND EIAV PERSISTENCE: OVERALL GOAL 
The long term goal of this study was to determine if variation in EIA V Rev 
contributes to EIA V persistence and clinical disease. Previous studies explored the 
significance of genetic variation within Rev in vivo through a longitudinal analysis of Rev 
within an experimentally infected horse, pony 524 (8). The results of these studies are 
summarized below, and provide the foundation of the studies described in Chapters 2 and 3. 
The hypothesis was that during the chronic stage of disease, the host is immunologically 
immature, and this environment would favor high phenotype Rev variants, and then, during 
the inapparent stage of disease, the host has mature immune response, and this would favor 
low phenotype Rev variants. 
Clinical disease course of Pony 524. The virulent Wyoming strain ofEIAV was 
used to infect pony 524(8). This inoculum was composed of a heterogeneous population of 
EIAV, similar to a natural infection. This pony exhibited a classical case of EIA, with an 
acute stage of disease, followed by a chronic stage ofrecurrent febrile episodes which 
decreased in frequency and severity over time (Fig. 2). Concurrent with maturation of the 
humoral immune response, this pony entered the inapparent stage of disease, which was then 
followed by two late febrile episodes. Sequential sera samples were collected throughout 
disease. 
Multiple subpopulations of EIA V Rev Quasispecies. From pony 524, 61 rev 
clones were obtained from the inoculum and 23-25 clones from each of the 11 sera samples 
collected throughout disease, for a total of 320 rev clones (8). There were 99 unique amino 
acid Rev variants, which exhibited a quasispecies distribution (8). Phylogenetic and partition 
analyses were used to characterize the Rev quasispecies of pony 524, and identified multiple 
subpopulations of EIAV Rev (5). A neighbor joining phylogenetic tree was calculated (Fig. 
3) for the 99 unique amino acid Rev variants, and showed a distinct branching pattern of the 
Rev quasispecies into two major clades, clade A and B, and one minor clade, clade C (5). 
Although there were more unique variants in clade A compared to clade B, these two clades 
were equally representative subpopulations of the quasi species with 156 and 153 clones, 
respectively. Variants from both subpopulation A and subpopulation B were observed at 
each stage of disease, but the two subpopulations exhibited distinct topologies throughout 
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disease (5,8). Subpopulation A was characterized by increased diversity and linear evolution 
over time, whereas subpopulation B, showed a radial distribution of variants at all stages of 
disease clustered around the variant R 1, the consensus sequence of the inoculum. Partition 
analysis of the quasispecies at each time point (Fig. 4A) revealed that these two major 
subpopulations of EIA V Rev coexisted throughout disease, and fluctuated in dominance in a 
manner coincident with disease state (5). Subpopulation A was dominant during the chronic 
and late chronic stages of disease, and subpopulation B was the dominant subpopulation 
during the inapparent stage of disease. Subpopulation C was always a minor subpopulation, 
observed in the inoculum, as well as, the inapparent and late chronic stages of disease. 
Phenotypically distinct subpopulations of EIA V Rev. The most frequently 
observed variants from each stage of disease were phenotyped for Rev nuclear export activity 
(8). The phenotype is reported relative to the variant R 1, the consensus of the inoculum, at 
100% relative Rev activity. Subpopulations A and B exhibited significantly different Rev 
phenotype. Variants of subpopulation A exhibited a high Rev phenotype, and variants of 
subpopulation B exhibited a low Rev phenotype. The average phenotype at each time point 
sampled is shown in Fig. 4B. A high Rev phenotype is observed during the chronic and late 
chronic stages of disease, when subpopulation A was dominant, and a low Rev phenotype 
was observed during the inapparent stage of disease, when subpopulation B was dominant. 
Goal and specific aims. The results of these studies support the overall hypothesis 
of the correlation of Rev phenotype and disease state, and provide insight into the 
mechanisms of quasispecies evolution in this pony. The coexistence of multiple 
subpopulations within a viral quasispecies, which differ in phenotype and selective 
advantage, suggests these subpopulations occupy different regions of a fitness landscape. 
The virus could then quickly adapt to changes in its environment, by expanding minor 
subpopulations that may be near the new fitness peak. The ability to rapidly adapt, may 
compensate for the cost of maintaining minor subpopulations that have reduced fitness 
relative to the dominant subpopulation. The goal of this thesis was to further characterize the 
genetic and phenotypic variation within and between subpopulations of EIAV Rev. The 
hypothesis was that specific amino acid changes within Rev alter fitness and contribute to 
selection of the subpopulations throughout disease. 
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The specific aims were: 
1. Identify amino acid mutations that contribute to the genetic segregation of 
Rev subpopulations A and B in pony 524; 
2. Determine the effect of these mutations on Rev phenotype; 
3. Determine which mutations contribute to EIAV Rev selection in vivo; 
4. Determine if multiple EIA V Rev subpopulations coexist in another EIA V-
infected horse. 
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FIG. 2. Clinical profile of pony 524. Stages of disease are indicated at the top of the 
figure. Fever episodes are indicated in columns on the Y-axis. Virus neutralizing 
antibody titer to EIA V wsu-s is indicated by the magenta line. Date of serum samples 
from which viral RNA was isolated are indicated along the X-axis. 
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FIG. 3. Neighbor-joining tree of the pony 524 Rev amino acid variants based on p-
distance. The tree is divided into three clades, designated A, B and C. The stage 
of disease from which the Rev variants were isolated is indicated by the color of its 
branch. Multicolored branches indicate variants isolated at multiple stages of 
disease. Highlighted variants were assayed for Rev activity. 
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CHAPTER 2. GENETIC AND PHENOTYPIC CHARACTERIZATION 
WITHIN AND BETWEEN SUBPOPULATIONS OF 
EQUINE INFECTIOUS ANEMIA VIRUS REV 
To be submitted to the Journal of Virology 
Wendy 0. Sparks 1, Sijun Liu1, Karin Dorman2•3, and Susan Carpenter1 
ABSTRACT 
Equine infectious anemia virus (EIA V) exhibits a high rate of genetic variation in 
vivo, and results in a clinically variable disease in infected horses. Previous studies identified 
two distinct subpopulations within the Rev quasispecies of an experimentally infected pony. 
The subpopulations showed significantly different phenotypes, as measured by in vitro 
assays, and fluctuated in dominance in a manner coincident with clinical stage of disease. 
This study characterizes the genetic changes within and between two subpopulations of 
EIAV Rev for changes in phenotype that may contribute to selection in vivo. The Rev 
protein was highly conserved, and only ten amino acid mutations were found at high 
frequency within the entire Rev quasi species. Nine of these amino acid mutations were 
capable of significantly altering Rev activity, either as a single mutation in the context of the 
founder variant Rl, or in the context of cumulatively fixed mutations. Phylogenetic analysis 
indicated nine of these ten mutations were fixed into the high Rev activity subpopulation 
over the course of disease. The fixation of the amino acid mutations, however, did not confer 
an increase in Rev activity over time, rather, maintained the high Rev phenotype of this 
subpopulation. Greater differences in Rev phenotype were observed between 
subpopulations, rather than within subpopulations of EIA V Rev as they evolved throughout 
disease. Further study of the evolutionary patterns of viral subpopulations will be 
1 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
2 Department of Statistics, Iowa State University 
3 Department of Genetics, Development, and Cellular Biology, Iowa State University 
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necessary to understand their contribution to lentiviral persistence. 
INTRODUCTION 
Lentiviruses exhibit a high mutation rate and exist as a population of closely related 
viral genotypes, termed a quasispecies (15, 17, 25). Studies have demonstrated that the 
evolution of viral quasi species adheres to the basic principles of population genetics, with 
mutation, recombination, natural selection, genetic drift and migration all acting as forces of 
evolutionary change, and that the entire population is the target of selection, not just 
individual viral variants (18, 32). The quasispecies occupies a region on a fitness landscape, 
in which adaptive mutations move the quasispecies to a fitness peak, resulting in an overall 
increase in fitness of the entire quasi species for the given environment. In HIV-1 , it is now 
recognized that the viral quasispecies observed in the plasma is composed of a dominant 
subpopulation, as well as, minor subpopulations that exhibit distinct genotypes and 
phenotypes (10, 12, 16, 30). Recent studies by Charpentier et al (10), have shown that a 
minor subpopulation, with distinct drug resistance genotypes, can eventually become the 
dominant subpopulation. Viral subpopulations can act as a reservoir of diversity and 
possibly increase the ability of a quasispecies to rapidly adapt to both pressures from the 
immune system and drug therapy. Greater understanding of the evolution within and 
between viral subpopulations is becoming increasingly important to both model disease 
progression and to predict the emergence of antigenic and drug resistant variants. 
Equine infectious anemia virus (EIA V) is a member of the lentivirus genus within the 
family of retroviruses. EIA V has the characteristic features shared by all lentiviruses, such as 
a complex genome, tropism for cells of the monocyte/macrophage lineage, and lifelong 
persistent infection. However, it is unique among lentiviruses in that it results in an acute 
dynamic disease course, characterized by recurrent cycles of fever, viremia and 
thrombocytopenia. Most animals survive this chronic stage of disease and eventually gain 
control of viral replication, progressing to an asymptomatic stage of disease. These animals 
then remain inapparent carriers of the virus for life. These characteristics make EIA V a good 
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model to study the role of both host and viral mechanisms contributing to lentiviral 
persistence and pathogenesis. 
High genetic variation has been observed in the EIA V rev/tm overlapping reading 
frame of the EIA V genome (Fig. 1 ), which encodes the regulatory protein Rev and the 
cytoplasmic tail of the transmembrane protein (2, 8, 27). Rev is an essential regulatory 
protein, which acts to transport partially spliced and unspliced RNA into the cytoplasm. 
These RNAs are translated into the structural proteins necessary for replication, as well as 
providing full length viral genomes for encapsidation. Recent studies in HIV-1, have 
identified positively selected sites within Rev, at proportions greater than the structural 
proteins (14). Cytotoxic T lymphocyte (CTL) epitopes have been identified within HIV-1 
Rev, as well (13). Variation in HIV-1 Rev activity has been shown to alter sensitivity to CTL 
killing, by down-regulating the expression of viral late genes (9). Furthermore, significant 
decreases could result from single amino acid substitution in HIV-1 Rev. Recent studies 
have identified CTL epitopes within EIA V Rev (29). Interestingly, in EIA V infected horses, 
nonprogressors exhibited strong avidity CTL response to epitopes within Rev, while 
progressors did not (29). Therefore, genetic changes within Rev may be critical to lentiviral 
persistence both in modulating Rev activity, and consequently expression of viral proteins 
and viral replication, as well as contributing to immune evasion. 
Previous studies examined the genetic and phenotypic variation of a Rev quasispecies 
through a longitudinal analysis of Rev throughout a clinically dynamic disease course in one 
pony experimentally infected with the virulent EIA V wv02078 (Fig. 2) (7). This pony exhibited 
a classical case of equine infectious anemia (EIA), with an acute stage of disease followed by 
a chronic stage of recurrent febrile episodes which decreased in frequency and severity over 
time. Concurrent with maturation of the hum oral immune response, this pony entered the 
inapparent stage of disease, which was then followed by two late febrile episodes. Rev 
variants isolated throughout disease exhibited a quasispecies distribution (7). Interestingly, 
phylogenetic and partition analyses identified multiple subpopulations of EIAV Rev (5). 
These subpopulations were independently evolving, coexisted throughout disease, and 
exhibited different phenotypes. Moreover, these phenotypically distinct subpopulations 
fluctuated in dominance in a manner coincident with disease state. The subpopulation with 
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higher Rev phenotype was dominant during the chronic and late chronic stages of disease, 
whereas, a subpopulation with lower Rev phenotype was dominant during the inapparent 
stage of disease (5,7). The emergence of new dominant genotypes observed within this pony 
was associated with the accumulation and fixation of mutations within a subpopulation and 
shifts in dominance from one subpopulation to another. 
In this study, we used genetic and biological analyses to characterize the genotypic 
variation both within and between the two subpopulations and its effect on phenotype. 
Results identified only nine amino acid positions within Rev that had a high degree of 
variation within the entire Rev quasispecies. Changes at seven of these nine positions could 
significantly alter Rev phenotype, both singly and in concert with other changes. These 
changes were predominately found only in the high Rev phenotype subpopulation, 
suggesting stronger purifying selection on the low rev phenotype subpopulation. The 
greatest change in fitness was observed between subpopulations of EIAV Rev, not within the 
evolving subpopulations. Of all single mutations, Ql 38R, present in the inoculum, had the 
largest effect on phenotype. This mutation was found in the high Rev phenotype 
subpopulation, and was observed throughout disease. A greater understanding of how these 
changes modulate Rev activity, and their association with specific stages of clinical disease 
may provide further insight into the mechanisms of lentiviral persistence and pathogenesis. 
MATERIALS AND METHODS 
Experimental infections and database of Rev variants. The virulent Wyoming 
strain of EIA V was used to infect pony 524, and sequential sera samples were collected from 
different stages of clinical disease as previously described (7). This inoculum is a 
heterogeneous population of EIAV, similar to a natural infection. From pony 524 61 rev 
clones were obtained from the inoculum and 23-25 clones from each of 11 sequential sera 
samples taken at 12, 35, 67, 89,118,201,289,385,437, 754, and 800 dpi for a total of320 
clones. All nucleotide sequences were translated into the Rev open reading frame. Amino 
acid variants were named in the order they were identified, with identical variants given the 
same name (7). 
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Genetic analysis of Rev quasispecies variation and evolution. The consensus 
sequence of the nucleotide sequences from the inoculum was calculated using Bioedit 5.0.9 
(23). The nucleotide consensus sequence of the inoculum corresponded to the rev variant 
RIA. Calculations of the rates of synonymous and nonsynonymous change in both the rev 
and tm reading frames were calculated using the software programs Bioedit (23) and MEGA 
2.1 (26) for the entire dataset, and by subpopulation. Standard error was estimated by 1000 
bootstraps. A positional summary of the nucleotide frequency at each position for the entire 
population of nucleotide variants was calculated using Bioedit (23). 
The amino acid consensus sequence the inoculum was calculated using BioEdit, and 
corresponded to the Rev amino acid variant Rl. This variant was used for comparison in 
both computational and biological analyses. A positional amino acid numerical summary 
was calculated using Bioedit vs. 7.0.1, and the frequency of nonconsensus amino acids 
within the entire population determined to characterize the overall genetic variation at each 
amino acid position within the population. The statistical significance of the variation at 
each position was determined by a student's t-test. High frequency amino acid mutations at 
these nine amino acid positions were identified within the entire Rev quasispecies, and their 
frequency within each subpopulation determined. 
High frequency amino acid mutations were then mapped onto the inferred phylogeny, 
which reflects the evolution of the Rev quasispecies over time. The fixation of these changes 
into the population is shown at critical bifurcations in the phylogeny, representing an inferred 
ancestral sequence. The stage of disease in which these mutations were fixed into the 
population is indicated. 
Site directed mutagenesis of Rev. Rev mutants were created via PCR mutagenesis. 
The template was the Rev expression vector pcH21 SL, which contains Rev cDNA in the 
pCR3 .1 (-) background (Invitrogen, Carlsbad, CA). This Rev expression vector was created 
from the Rev expression vector pcH21 (8), which contains the cDNA in pCR3 background 
(Invitrogen, Carlsbad, CA). The rev cDNA in pcH21 SL contains the first exon of rev from 
pcH21, and the second exon is the nucleotide sequence of variant R 1 A. Forward and reverse 
primers containing the desired mutation were used in a series of PCR reactions along with 
forward and reverse primers located in the vector backbone of PCR3 .1 (-). The first reaction 
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used the forward vector primer and the reverse mutant primer within rev, the second reaction 
used the reverse vector primer and the forward mutant primer. The template for the single 
mutations was the Rev expression vector pcH21 SL, and those with multiple mutations were 
amplified from prior PCR reactions. The PCR reaction consisted of 1 uL each of forward and 
reverse primers (50pmol/uL), l0uL l0X Pfu Buffer, luL dNTPs l00mM, luL Pfu DNA 
polymerase, 1 uL DNA template at 50ng/uL and 85 ul ddH20. PCR amplification conditions 
consisted of 30 cycles of denaturation at 94°C for 1 minute, annealing at 58°C for 1 minute, 
and extension at 72°C for 1 minute. The initial and final cycles contained a prolonged 
extension at 72°C for 2 minutes and 8 minutes, respectively. PCR products were separated 
by gel electrophoresis on a 1 % agarose gel, excised, and purified using QIAquick gel 
extraction kit (Qiagen), and eluted in 50uL elution buffer. A third PCR reaction using 5uL of 
each of the first and second PCR reactions as template was performed with the forward and 
reverse vector primers, total volume 1 00uL. The PCR reactions conditions consisted of 30 
cycles of 94°C 1 min, 58°C 1 min, 72°C 2 min, link to 72°C 8 minutes. This product was gel 
purified as described for reactions 1 and 2. The final PCR product of reaction 3 was digested 
with Apal and Kpnl, and then ligated into corresponding sites in the Rev expression vector 
pcH21 SL· Mutant inserts were screened using restriction mapping, and mutations confirmed 
by sequencing. 
Assays of Rev nuclear export activity. The Rev nuclear export activity of each of 
the mutants was determined in transient transfection assays using pDM138-based CAT 
reporter plasmid, pERRE-All, containing EIA V RRE (nt 5280-7534) and the 
chloramphenicol acetyltransferase (CAT) gene (8). 293 cells were seeded in triplicate at 1-
5x105 cells/well in 6-well tissue culture dishes, and transfected with 0.2 µg of pERRE-All, 
0.2µg of P-galactosidase reporter plasmid pCHl 10 (Pharmacia, Uppsala, Sweden), 1 µg of 
Rev expression plasmid or empty vector along with 0.60 µg pUC19 for a total of 2 µg DNA 
per reaction. Each experiment included a sham group which contained no reporter plasmid, 
but an additional 0.2 µg of pUCl 9. At 48 hours post transfection, cells were harvested in 
phosphate-buffered saline (PBS) containing 0.5 mM EDT A, pelleted, and resuspended in 500 
µl 0.25 M Tris, pH 7.5, and lysed by three rounds of freeze-thawing. Normalized cell lysates 
were assayed for P-galactosidase activity and these values used to normalize for transfection 
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efficiency. Cell lysates were assayed for CAT enzyme using a commercial CAT ELISA kit 
(Roche Molecular Biochemicals, Indianapolis, IN). Experiments were performed in 
triplicate, and results represent at least 6 independent transfections. Statistical analysis was 
performed using analysis of variance (ANOVA) and student's t-test assuming unequal 
variance among groups. 
Nucleotide sequence accession numbers. GenBank accession numbers are 
AF314257 to AF314404. 
RESULTS 
Rev quasispecies characterized in EIA V infected pony. Following experimental 
infection, pony 524 experienced a variable disease course characterized by recurring fever 
cycles interspersed with afebrile periods ranging from days to months (Fig. 2). The onset of 
the inapparent stage was associated with the maturation of the host immune response and a 
significant decrease in Rev activity (7). The rev exon 2/tm overlapping region of EIA V was 
amplified via RT-PCR from RNA isolated from the inoculum and sequential sera samples 
taken throughout disease. This resulted in a Rev data set of 320 clones, in which there were 
146 unique nucleotide variants and 99 unique amino acid variants. The amino acid variant 
Rl, was the consensus sequence of the inoculum, and the most frequently observed variant 
overall. All genotypic and phenotypic analyses were performed relative to RlA, which was 
the dominant nucleotide sequence encoding the amino acid variant Rl. 
EIA V Rev quasispecies shows high genetic variation at a minority of positions. 
To assess the genetic variation of the Rev quasispecies, the overall rates of nonsynonymous 
and synonymous substitution were calculated, as well as the variation observed at each 
nucleotide position. Calculations of dN, dS, and dN/dS for the entire population of 320 
clones, and by subpopulation are shown in Table 1. All results indicated that rev, as a whole, 
was under purifying selection. This was true over the entire quasispecies, and within 
subpopulations. To assess the genetic variation at each nucleotide position the frequency of 
nucleotides differing from RIA at each position was calculated over the entire dataset of 320 
clones (data not shown). Overall, 278 of the 405 nucleotide positions observed throughout 
rev/tm were conserved in both reading frames. The remaining 127 nucleotide positions 
showed varying frequencies of change. Thirteen nucleotide positions exhibited change at a 
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frequency greater than 0.10 of the total population. Of these, nine were non-synonymous in 
both rev and tm, three were non-synonymous only in tm, and one was non-synonymous only 
mrev. 
The frequency of amino acid change from variant Rl at each position in Rev is shown 
in Figure 3A. Ten nucleotide positions showed a high frequency of nonsynonymous change, 
however, mutations at two adjacent nucleotides positions resulted in mutations at a single 
amino acid position; consequently, there were nine highly variable amino acid positions in 
Rev. The frequency of the mutations observed at these nine amino acid positions ranged 
from 11 % to 51 % of the entire Rev quasispecies, and was significantly greater than the 
average variation of the 135 amino acid positions in Rev (p<0.000001). Five of these 
positions were located within or adjacent to functional domains of Rev. Position 55 is 
located within the nuclear export signal (20, 28), positions 105 through 127 in a region 
essential to Rev function, and positions 134 through 143 in a region non-essential for Rev 
function (33). Closer examination of these nine positions reveals that the majority of these 
positions have only one to two amino acid mutations (Fig. 3B). Further, each position has 
only one amino acid mutation observed at a frequency greater than or equal to 0.10. The 
only exception to this was position 55, in which two amino acid mutations were observed at a 
frequency greater than or equal to 0.10. Interestingly, the nucleotide mutation resulting in 
the praline at position 55 is the only mutation which did not cause an amino acid mutation in 
TM as well. 
Single amino acid mutations significantly alter Rev phenotype. Since the 
nucleotide changes altered the amino acid sequence of both Rev and TM, it was of interest 
which, if any, of the individual genotypic mutations altered Rev phenotype. Each of the ten 
single amino acid mutations was introduced in the backbone of Rl, the consensus of the 
inoculum (Fig. 4A). Rev nuclear export activity was quantified using transient transfection 
assays and activity was normalized relative to Rl. Results indicated that seven of these ten 
amino acid mutations significantly altered Rev phenotype, while three were not significantly 
different than the activity of Rl (Fig. 4B). Six of the seven mutations resulted in an increase 
in Rev activity, while one mutation resulted in a decrease in Rev activity. Both mutations at 
position 55, in the NES, increased Rev activity, as well as two mutations in the essential 
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region and two mutations in the non-essential region of Rev. The mutation at position 134, 
located in a region non-essential to Rev function, was the only single mutation to cause a 
significant decrease in Rev activity. Interestingly, many of these mutations involved large 
changes in size or charge of the amino acid. 
Nonrandom distribution of mutations between Rev subpopulations. To 
determine which of these ten amino acid mutations were contributing to the genotypic 
segregation between the two subpopulations, the frequency of the amino acids at each of 
these nine highly variable positions was then examined within each subpopulation (Fig. 5). 
The two subpopulations exhibited very different distributions of the amino acids observed at 
these nine positions. The Rl consensus amino amid was observed in both subpopulations at 
almost every position. The mutations, however, were observed at high frequency in only one 
subpopulation or the other. Moreover, nine of the mutations were found in subpopulation A, 
and only one mutation was observed at high frequency in subpopulation B. 
Notably, two mutations were the dominant amino acid in subpopulation A, at 
positions 138 and 135. The entire subpopulation contained the mutation Q138R, and a great 
majority the mutation D135G. These two mutations were not observed at high frequency in 
subpopulation B, demonstrating a clear distinction between the two subpopulations. The 
mutations at the remaining seven positions were all observed at a high frequency only within 
subpopulation A, and not in subpopulation B, with the exception of position 55. Position 55 
was the only position where two mutations were observed at a high frequency within the 
entire Rev quasispecies. Interestingly, the mutation S55P was found only in subpopulation 
A, and the mutation S55L was found at high frequency only in subpopulation B. Moreover, 
the mutation S55L was the only mutation observed at a high frequency in subpopulation B. 
These high frequency mutations were not evenly distributed between both subpopulations, no 
mutations were found at a high frequency in both subpopulations, and each mutation 
contributed to the genotypic segregation of the two subpopulations. 
Fixation of preexisting and in vivo mutations in EIAV Rev. To determine how 
these mutations were related to the temporal evolution of EIAV Rev, we mapped these 
mutations onto the inferred phylogenetic tree (Fig. 6). This allows a visual representation of 
the fixation of the mutations observed in the Rev quasispecies throughout the course of 
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disease in vivo (Fig. 2). Of the ten high frequency amino acid mutations observed, four were 
preexisting mutations found in the inoculum, fixed in the early stage of infection, and 
persisting throughout the course of disease. This included the mutations D 135G and Q l 38R, 
which were dominant amino acids in subpopulation A. These two mutations were found at 
the internal nodes of the tree, illustrating the initial division of the quasispecies into 
subpopulations A and B. Also present in the inoculum, was G 134D, found in subpopulation 
A, and observed throughout the inapparent stage of disease. The only mutation fixed in sub-
population A, S55L, was also preexisting in the inoculum. This mutation was observed 
throughout the inapparent stage of disease, though not in the late chronic stage of disease. 
The remaining six mutations were found at high frequency only in subpopulation A, 
and were fixed into the subpopulation throughout the course of disease; one to two mutations 
associated with each clinical stage of disease in the pony. The accumulation and fixation of 
mutations was observed both when subpopulation A was the majority subpopulation, as well 
as when it was the minority subpopulation. The inferred phylogeny of subpopulation A was 
composed of two main branches. One branch exhibited a more radial distribution, similar to 
subpopulation B, while the other branch exhibited a more divergent, linear evolution. The 
G 134D mutation, present in the inoculum, defined the radial branch of subpopulation A, and 
another mutation, Vl 12A, was fixed into this branch near the end of the acute stage of 
disease. Variants of this branch of subpopulation A were dominant in the first two time 
points of the chronic stage of disease, and while no further high frequency mutations were 
observed, variants of this branch persisted throughout the last time point of the inapparent 
stage of disease. 
Within the divergent branch of subpopulation A, variants grouped by day, and the 
phylogeny reflected the sequential fixation of five amino acid mutations over time. This 
branch of subpopulation A reflects the evolution from the latter time points of the chronic 
stage of disease throughout the late chronic stage of disease. The mutation Rl 27K was fixed 
bydpi 118 of the chronic stage of disease, followed by Gl l0D and V105A at dpi 201, of the 
inapparent stage of disease, culminating with the simultaneous fixation of S55P and Rl 43H 
at dpi 754, during the late chronic stage of disease. At dpi 800, 91 % of the variants sampled 
contained these 7 amino acid changes. Variants of this branch of the phylogeny were 
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dominant in the latter part of the chronic stage of disease, and again in the late chronic stage 
of disease. 
Subpopulation B did not show a temporal evolution with fixation of mutations. The 
mutation S55L, the only high frequency mutation observed in subpopulation B, was 
preexisting in the inoculum. Although variants containing this mutation were observed in the 
inoculum, acute, and inapparent stages of disease, this was due to the recurrence of variants 
which had been observed previously, not new variants which had the S55L mutation. 
Variant Rl was the dominant Rev genotype of subpopulation B at all time points sampled, 
both as the dominant and minor subpopulation. In summary, the evolution of the Rev 
quasispecies of pony 524 was characterized by the fixation of four preexisting mutations 
observed in the inoculum, and six mutations which arose throughout the course of disease in 
vivo. Nine of the ten mutations were specific to subpopulation A, the subpopulation with 
significantly greater relative Rev activity (5). The cumulative fixation of these nine 
mutations into subpopulation A throughout disease could confer greater fitness, and explain, 
in part, the shift in dominance from subpopulation B, in the inapparent stage of disease, back 
to subpopulation A during the late chronic stage. 
Evolution of Rev subpopulations maintains relative Rev activity. To determine if 
the cumulative fixation of these mutations as observed in vivo conferred greater fitness, as 
greater relative Rev activity, a series of evolution mutant constructs were created and 
phenotyped. These constructs represent the evolution of each subpopulation throughout 
disease, at these nine variable amino acid positions (Fig. 7 A). The constructs are sorted into 
three groups of mutation combinations shown as preexisting, in vivo, and possible ancestors. 
The relative Rev activity of these evolution mutant constructs is shown in Fig. 7B. 
The first group of evolution mutant constructs includes the four preexisting mutations 
in the combinations observed in the inoculum. One of the preexisting mutations observed 
was S55L, the only high frequency mutation observed in subpopulation B, and is represented 
by the mutant EvolB-1. This mutation was present throughout the inapparent stage of 
disease, though was never the dominant genotype of subpopulation B. The Rev activity of 
EvolB-1 was 139%, significantly greater than the Rev activity of the standard R 1, the 
consensus sequence of the inoculum. The evolution mutant constructs representing the 
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combination of the three preexisting mutations as observed in vivo in subpopulation A are 
EvolA-1, EvolA-2, and EvolA-3 . EvolA-1 contains only the Q138R mutation in the 
backbone ofRl, and resulted in a significant increase in relative Rev activity to 183%. The 
addition of the D135G, in construct EvolA-2, significantly increased Rev activity to 221 %. 
The addition of the mutation G 134D, construct EvolA-3, resulted in a decrease in Rev 
phenotype to 131 %. This phenotype was significantly greater than Rl (p < 0.0005), and was 
also significantly less than the Rev activity of EvolA-1 (p < 0.0005). The Rev activity of 
EvolA-3 was not significantly different from EvolB-1. 
The six mutations which arose in vivo were all fixed into subpopulation A throughout 
the course of clinical disease. The constructs EvolA-4 through EvolA-8 represent the 
cumulative addition of these mutations as observed in vivo. EvolA-4 represents the addition 
of the Vl 12A mutation into the EvolA-3 backbone. This mutation was fixed by the last time 
point of the acute stage of disease, and this combination of mutations was observed in the 
radial subclade of subpopulation A, which was not present during the late chronic stage of 
disease. The Rev activity of EvolA-4 was 176%, which is significantly greater than Rl (p < 
0.0005), and EvolA-3 ( p< 0.005), though not significantly different than EvolA-1. The 
constructs EvolA-5 through EvolA-8 represent the cumulative fixation of the five remaining 
mutations along the linear evolving branch of subpopulation A, in the backbone of EvolA-2. 
These mutants do not contain the mutation G134D. The mutant construct EvolA-5 contains 
the mutation R127K, fixed during the inapparent stage of disease, and had an activity of 
187%. The activity of EvolA-5 was significantly greater than Rl (p<0.0005), and 
significantly less than EvolA-2 (p<0.01), however, it was not significantly greater than 
EvolA-1. EvolA-6, with the addition of the Gl l0D mutation, had a relative Rev activity of 
185%. This, too, was significantly greater than R 1 (p< 0.005), but not significantly different 
from EvolA-1. The construct EvolA-7, with the addition of Vl 05A, had relative Rev activity 
of 236%, which was significantly greater than both Rl (p<0.0005), and EvolA-1 (p<0.05). 
EvolA-8 reflects the simultaneous fixation of mutations S55P and R143H into the backbone 
of EvolA-7, and had a phenotype of 182%. As with the mutant constructs EvolA-4, EvolA-
5, and EvolA-6, EvolA-8 was significantly greater than Rl, but was not significantly 
different from EvolA-1. The relative Rev activity of these five evolution mutant constructs 
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reflecting the cumulative fixation of the six in vivo mutations into subpopulation A were all 
significantly greater than the variant Rl, the consensus of the inoculum and the dominant 
variant of subpopulation B. However, the cumulative fixation did not select for ever 
increasing relative Rev activity. In fact , four of the five had Rev activity that was not 
significantly different from one another, or the mutant construct EvolA-1. This suggests that 
these mutations served to maintain a relative Rev activity near 180%. EvolA-4, EvolA-5, 
and EvolA-8 all contain mutations which could be considered compensatory mutations, 
which returned Rev phenotype to near 180% from phenotypes above and below this activity. 
EvolA-4 followed EvolA-3 with an activity of 131 %, EvolA-5 followed EvolA-2 with an 
activity of 221 %, and EvolA-8 followed EvolA-7 which had an activity of 236%. 
The last set of evolution constructs is composed of two possible ancestral sequences. 
The mutant construct EvolA-8 contained two mutations, S55P and R143H, which were 
observed simultaneously in vivo. The relative Rev activity of EvolA-8 was not significantly 
different than EvolA-1, but was significantly less than its predecessor, EvolA-7 (p<0.05). To 
determine if these two mutations had independent effects on Rev phenotype, or acted as 
compensatory mutations, the constructs EvolA-9 and EvolA-10 were created. These two 
mutant constructs represent two possible ancestral sequences to EvolA-8. EvolA-9 contains 
the mutation S55P in the backbone ofEvolA-7, and EvolA-10 contains the mutation R143H 
in the backbone of EvolA-7. EvolA-9 had an activity of 231 %, which was not significantly 
different than EvolA-7. EvolA-10, however, had an activity of 159%, which was 
significantly different than EvolA-7 (p<0.005). Interestingly, both EvolA-9 and EvolA-10 
were significantly different than their successor, EvolA-8, with an activity of 182% (p<0.01, 
p<0.05, respectively). Theoretically, either of these two mutations could have arisen first, 
and then been followed by the other to restore relative Rev activity to a level near that of 
EvolA-1. 
These results suggest that selection on subpopulation A was to maintain a Rev 
phenotype near 180% relative Rev activity, near that ofEvolA-1. The mean ofEvolA-1, 
EvolA-4, EvolA-5, EvolA-6, and EvolA-8 was 182%. Variants containing only the 
combination of mutations created in the mutant constructs with significantly greater (EvolA-
2, EvolA-7, EvolA-9) or significantly lower (EvolA-3, EvolA-10) relative Rev activity than 
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EvolA-1 were observed transiently in vivo, or not at all. EvolA-2 and EvolA-3 were present 
in the inoculum, and at low frequency during the acute and chronic stages of disease, 
whereas EvolA-7, EvolA-9, and EvolA-10 were not observed by the sampling of Rev 
variants of this pony. The variants observed contained other mutations in addition to those in 
these mutant constructs. Most of the in vivo variants phenotyped had relative Rev activity 
less than 200% (7), suggesting there was selection against Rev phenotypes greater than 200% 
relative Rev activity in vivo. 
Likewise, subpopulation B also maintained its phenotype, though this was due to the 
purifying selection on this subpopulation. Only one mutation was observed at high 
frequency within this subpopulation, and it never became dominant over the consensus 
amino acid ofRl. The phenotypes of these nine mutant constructs of subpopulation A and 
the one mutant construct and variant Rl from subpopulation B were significantly different 
from one another (p<0.0005), and 53% of the variation between the two subpopulations 
could be explained by the difference in subpopulation means. 
Effect of mutations on Rev phenotype is context dependent. Interestingly, the 
effect of the cumulative fixation of these mutations, represented by the evolution mutants, 
could not be predicted by the results of the single mutant phenotypes. Table 2 shows the 
relative effect of each mutation, both as a single mutation in the backbone of R 1, and in the 
context of the cumulative fixed mutations. The mutations S55L and Ql 38R, were only 
observed as single mutations, since no further mutations were fixed in subpopulation B, and 
all variants of subpopulation A contained the Q l 38R mutation. The mutation D 135G, 
appeared to be an additive mutation, causing the same relative increase in Rev phenotype 
both singly, and as cumulative mutation with Q138R. G134D, however, had a greater effect 
on phenotype in the context of the cumulative mutations. The mutation Vl 12A appeared to 
be another additive mutation, increasing the relative Rev activity in either background. The 
mutation R127K, which had no effect on Rev phenotype in the background ofRl, caused a 
significant decrease in Rev phenotype in the context of the cumulative mutations Q138R and 
D135G. Interestingly, the mutation Gl l0D, which had a phenotype of207% as a single 
mutation in the background ofRl, had no effect on Rev phenotype as a cumulative mutation. 
Vice versa, the mutation V 105A, which had no effect in the R 1 background, resulted in a 
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significant increase in Rev phenotype in the background of cumulative mutations. The last 
two mutations, observed simultaneously in vivo, together resulted in a decrease in Rev 
phenotype. Individually, the mutation S55P, which increased Rev phenotype in the Rl 
background, had no effect in the background of cumulative mutations of EvolA-7. The 
mutation Rl43H, however, resulted in a significant decrease in Rev phenotype in the 
background of cumulative mutations, though it had no effect in the background of Rl. Some 
mutations appeared additive, having the same effect on phenotype, regardless of the context 
of other amino acids, whereas others had a greater effect when in the context of cumulative 
fixed mutations. Yet others seemed to reverse roles depending on the context, having no 
effect singly, but causing significant change in the background of cumulative mutations, and 
vice versa. Many of these changes involve large changes in charge and size, and their 
placement in the Rev protein structure will be key into gaining further understanding of how 
these changes modulate Rev activity in a context dependent manner. 
DISCUSSION 
Lentiviruses are characterized by high rates of mutation, recombination, and 
replication, resulting in a diverse population of viral variants, termed a quasispecies (15, 17, 
25). These characteristics of lentiviruses, as well as migration, viral memory, and genetic 
drift are thought to contribute to the ability of lentiviral quasispecies to rapidly adapt in 
response to selective pressures (12, 22, 32). Previous work identified two subpopulations of 
EIA V Rev within pony 524 (5). These two subpopulations coexisted throughout disease, and 
variants from each subpopulation were present at each stage of disease. Moreover, these two 
subpopulations fluctuated in dominance in a manner coincident with disease state; 
subpopulation A was the majority subpopulation in the chronic and late chronic stages of 
disease, and subpopulation B was the majority subpopulation during the inapparent stage of 
disease (Fig. 2). Dominant variants of subpopulation A had significantly greater Rev activity 
than those of subpopulation B (5, 7). To further understand changes in these two EIA V Rev 
subpopulations due to selective pressures throughout disease, we characterized the genetic 
differences within and between Rev subpopulations, and their effect on Rev phenotype. Our 
results, which show greater differences in Rev phenotype between subpopulations of Rev, 
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rather than within a subpopulation, further underscore both the sensitivity of Rev to single 
amino acid mutations, as well as, the role of viral subpopulations throughout disease. 
The results of both genetic and phenotypic analyses suggest that Rev activity is 
highly sensitive to amino acid mutation. Genetic analyses of the nucleotide sequences found 
the majority of nucleotide positions to be conserved within both the rev and tm reading 
frames, and suggested this region was under purifying selection in the entire rev 
quasispecies, and within each of the subpopulations. Likewise, the majority of the amino 
acid positions were conserved in both the Rev and TM reading frame. Within the population 
of 320 Rev clones, 121 of 135 amino acid positions varied by less than 2%, and 70 amino 
acid positions were 100% conserved. There were only ten amino acid mutations observed 
within the Rev quasispecies observed at a high frequency (p<0.00001). Phenotypic analysis 
of these single mutations, introduced into the backbone of the Rev variant Rl , the founder 
variant of the inoculum, determined seven of the ten single amino acid mutations could 
significantly alter Rev phenotype. Only two of these ten high frequency mutations were 
observed singly in vivo, S55L and Q138R. Both mutations caused significant increases in 
Rev activity. 
Previous phenotyping of the most frequently observed in vivo variants from pony 524 
identified a Rev phenotype range of 63% to 221 % relative Rev activity (7) . Two of the ten 
single amino acid mutations studied here were capable of increasing or decreasing Rev 
phenotype, relative to Rl, to levels near the range limits observed in vivo. D134G had an 
activity of 80%, and G 11 OD had an activity of 207%. Interestingly, these two single 
mutations were never observed singly in vivo in this pony, rather, they were found only in the 
context of other high frequency mutations. 
Also, of note, two mutations which did not cause a significant change in Rev activity 
within the context of Rl, were capable of significantly altering Rev phenotype when in the 
context of other high frequency mutations. Evol-A 7, with the addition of Vl 05A, resulted in 
a significant increase in Rev activity, and EvolA-10, with the addition ofR143H caused a 
significant decrease in Rev phenotype. This suggests that certain amino acid mutations will 
be favored only in a specific context. Overall, these results suggest great purifying selection 
on Rev, and great sensitivity to amino acid mutations in a context dependent manner. 
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These two subpopulations of EIAV Rev in pony 524 exhibited different evolutionary 
patterns throughout disease, as described previously (5). Subpopulation B exhibited a radial 
distribution around a central founder variant, Rl, while subpopulation A exhibited 
divergence over time. The results of this study provide greater detail of the evolution of 
these two subpopulations of Rev. Nine amino acid mutations were fixed into subpopulation 
A, through the accumulation and fixation of these mutations in two distinct branches of this 
subpopulation. Two mutations were common to both branches of subpopulation A, while the 
remaining seven mutations split unequally; two in the radial branch, and five fixed into the 
divergent branch. Interestingly, subpopulation A continued to evolve throughout all stages of 
disease. Subpopulation A accumulated and fixed mutations both as the dominant 
subpopulation during chronic stages of disease, and as the minor subpopulation during the 
inapparent stage of disease. Subpopulation B, in contrast, exhibited little linear divergent 
evolution through the accumulation and fixation of mutations. Only one amino acid mutation 
was observed at high frequency in this Rev subpopulation, S55L, and this mutation never 
became part of the master genotype of this subpopulation. However, this mutation did persist 
at low levels throughout the inapparent stage of disease. 
The phenotype of these mutations shows how these mutations modulate Rev 
phenotype in the context observed in vivo. The consecutive fixation of the mutations 
observed in subpopulation A maintained Rev activity at a level similar to EvolA-1, with an 
activity of 183%, rather than continuously selecting mutations which conferred higher Rev 
activity. Both increases and decreases in Rev activity were observed within this 
subpopulation, but were followed by mutations which restored Rev phenotype to levels near 
EvolA-1. The fixation of G 134D, resulting in a decrease in activity to 131 %, was followed 
by the fixation of mutant Vl 12A, resulting in an increase in relative Rev activity to 176%. 
Likewise, EvolA-2, with an activity of221 %, was followed by fixation ofR127K, and 
resulted in a decrease in relative Rev activity to 187%. The two mutants representing 
possible ancestral sequences exhibited Rev activity significantly different than EvolA-1, as 
well, but the presence of both, resulted in activity of 182%. It is unclear whether this 
evolution of subpopulation A reflects random fixation of mutations through genetic drift, 
followed by compensatory mutations to maintain a level of Rev activity near 180%, or if 
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these mutations confer selective advantage in the face of the immune pressures from the host, 
with compensatory mutations to maintain the level of Rev activity. Selection could also be 
acting on Rev in another manner, which has not been measured. Subpopulation B, in 
contrast, exhibited little divergent evolution, and only one mutation was fixed into this 
subpopulation. Though never a dominant mutation, it did cause a significant increase in Rev 
activity, to 138%. 
The phenotype results of these mutants from both subpopulations, reflecting the 
fixation of these ten high frequency amino acid mutations, indicate that differences in Rev 
activity were greater between the two subpopulations, than within Rev subpopulations (p< 
0.0005), and that 53% of the variation observed could be explained by the assignment of Rev 
variants into subpopulation A and B. Moreover, in vivo, the greatest increase in relative Rev 
activity was due to a single amino acid mutation, Q138R. This mutation was present in the 
inoculum and all variants of subpopulation A contained this mutation. Subsequent mutations 
could increase the level ofrelative Rev activity even higher, but the difference in activity was 
not as great as that of the mutation Q 13 SR and the variant R 1. These results are consistent 
with other studies which have identified greater fitness differences between viral 
subpopulations, rather than within ( 4, 31, 35), and that the greatest fitness increases are fixed 
early on, when they confer the greatest advantage (32). 
The results of this study support the increasing body of evidence that a viral 
quasispecies is composed of multiple independently evolving, phenotypically distinct 
subpopulations. These subpopulations provide greater adaptability to the viral quasispecies 
over time, despite the cost of maintaining less fit subpopulations of viral variants. Several 
studies have described genetically distinct populations ofHIV-1 both between and within 
different infected tissues and organs (1, 19, 36, 39-41), as well as in cells of the immune 
system which may remain latent for years ( 6, 11, 21 ). Recent studies have shown multiple 
subpopulations of HIV-I to coexist within the host, evolve differently, as well as the ability 
of a latent subpopulation to recrudesce and become dominant ( 6, 10, 21 ). The emergence of 
a new dominant master sequence of the quasi species results from either mutation of the 
existing subpopulation, or a shift to a minor subpopulation or latent subpopulation (10). 
These minor subpopulations continue to evolve over time, can become the dominant 
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sequence of the quasispecies, and act as reservoirs of memory genotypes, all which allow the 
virus to rapidly evolve to a changing environment. Studies of other RNA virus populations, 
in which sites of positive selection have been identified, have also observed quasispecies 
shifts as a response to environmental changes, not a slower response via the accumulation of 
point mutations (3, 6, 21, 34). 
Although the dominant EIA V Rev genotype observed in pony 524 changed six times 
throughout disease, we see changes in disease stage only when there is a shift in the 
dominant subpopulation of Rev. These results suggest multiple subpopulations, with distinct 
genotypes and phenotypes, play an important role in the evolution of the Rev quasispecies 
and EIA disease. Interestingly, subpopulation A continued to evolve during the inapparent 
stage of disease, when it was a minor subpopulation. When this subpopulation re-emerged as 
the dominant subpopulation in the late chronic stage of disease, it contained several new 
mutations. Further studies of the genotypic and phenotypic changes within and between 
subpopulations of EIAV, and their correlation with clinical disease will further our 
understanding of quasispecies evolution and lentiviral persistence. 
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TABLE. 1. Rate of substitution in Rev quasispecies. 
Group n dSa S.Eb dNC S.E. dN/dSd 
Entire Population 320 
rev 0.017 0.005 0.013 0.004 0.765 
tm 0.011 0.005 0.016 0.004 1.455 
Subpopulation A 156 
rev 0.015 0.006 0.014 0.004 0.933 
tm 0.011 0.005 0.015 0.004 1.364 
Subpopulation B 153 
rev 0.013 0.006 0.004 0.002 0.308 
tm 0.009 0.005 0.005 0.002 0.556 
Subpopulation C 11 
rev 0.032 0.012 0.015 0.005 0.469 
tm 0.020 0.011 0.019 0.005 0.950 
a The rate of synonymous substitution calculated using the Nei-Gojobori method with a 
Jukes-Cantor correction. 
b Standard error was estimated from 1000 bootstrap replicates. 
c The rate of nonsynonymous substitution calculated using the Nei-Gojobori method 
with a Jukes-Cantor correction. 
d The dN/dS ratios are shown for both the rev and the tm reading frame over the entire 
population and within each subpopulation. 
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TABLE 2. Effect of mutations on Rev phenotype. 
Mutanta Singleb Cumulativec 
Preexisting 
S55L +d +e 
Q138R ++ ++ 
O135G + + 
G134D 
in vivo 
V112A + + 
R127K 0 
G110D +++ 0 
V105A 0 + 
S55P/R143H NA 
in vitro 
S55P + 0 
R143H 0 
a The ten mutations listed in the order they were fixed into the population. 
b The effect of the mutation as a single mutation, in the backbone of variant R 1, 
the consensus of the inoculum. 
c The effect of the mutation in the context of other mutations fixed into the 
population. 
d The relative effect on phenotype compared to Rl. + indicates a quartile increase 
in relative Rev activity, - indicates a quartile decrease in relative Rev activity, and 0 
indicates no change. 
e The relative effect on phenotype compared to the previous mutant. + indicates a 
quartile increase in relative Rev activity, - indicates a quartile decrease in relative 
Rev activity, and O indicates no change. 
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CHAPTER 3. CHARACTERIZATION OF EQUINE INFECTIOUS 
ANEMIA VIRUS REV IN ANOTHER INFECTED PONY 
1 I Oak 2 C 1 W.O. Sparks, R.J. Thompson, J.L. s, S. arpenter 
( extracted in part from publication in Journal of Virology Nov. 2003 p 12122-12131 
Subpopulations of equine infectious anemia virus Rev coexist 
in vivo and differ in phenotype 
P. Baccam1'4, R.J. Thompson1, Y. Li 1, W.O. Sparks1, M. Belshan, 1 K. Dorman, 2'3 
I - 4 I Y. Wannemuehler, J.L. Oaks," J.L. Cornette , and S. Carpenter) 
ABSTRACT 
Lentiviruses exist in vivo as a population ofrelated, non-identical genotypes, commonly 
referred to as quasispecies. The quasispecies structure is characteristic of complex adaptive 
systems and contributes to the high rate of evolution in lentiviruses that confounds efforts to 
develop effective vaccines and antiviral therapies. Previous studies identified two distinct 
subpopulations within the Rev quasispecies of an experimentally infected pony. The sub-
populations showed significantly different phenotypes, and the sub-populations fluctuated in 
dominance in a manner coincident with clinical stage of disease. Here, we describe variation 
in a lentivirus regulatory protein, Rev, throughout a longitudinal course of disease in another 
pony experimentally infected with equine infectious anemia virus. Rev variants from this 
pony exhibited a quasispecies distribution, similar to that observed in previous studies. 
Phylogenetic and partition analyses revealed the presence of two sub-populations of Rev that 
differed in phenotype. The coexistence of genetically distinct viral subpopulations that differ 
in phenotype provides great adaptability to environmental changes within the infected host. 
A quasispecies model with multiple subpopulations may provide additional insight into the 
nature of lentivirus reservoirs and the evolution of antigenic and drug resistant variants. 
1Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
2Department of Veterinary Microbiology and Pathology, Washington State University 
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INTRODUCTION 
Lentiviruses exhibit high mutation rates and exist in vivo as a population of closely 
related viral genotypes that are commonly referred to as a quasispecies (10, 12, 17). The 
population structure of a quasispecies consists of a master sequence, which is the dominant 
genotype, and the mutant spectrum, which includes reservoirs of genotypic and phenotypic 
variant~ with the potential to become dominant in the face of environmental change. Studies 
have demonstrated that the evolution of viral quasispecies adheres to basic principles of 
population genetics; however, quasispecies theory diverges from population genetics in that 
the entire deme ofrelated sequences, rather than the individual replicon, is the main target of 
selection (13). The quasispecies occupies a region on a fitness landscape where adaptive 
mutations move the quasispecies toward a fitness peak, thereby increasing the mean fitness 
of the quasispecies. Understanding the principles that shape the evolution of viral 
quasispecies is becoming increasingly important as molecular information is used to model 
disease progression and to predict the emergence of antigenic and drug-resistant variants. 
Experimental infection of horses with equine infectious anemia virus (EIA V) 
provides an excellent system for longitudinal studies of lentiviral evolution during disease 
progression. EIA V is a lentivirus that is genetically, antigenically, and morphologically 
related to human immunodeficiency virus type 1 (HIV-1) (14, 19, 28). EIAV causes 
reproducible clinical disease course with progression of clearly demarcated stages of disease 
in infected horses (15, 18, 20, 25). Following infection, horses may exhibit an early episode 
of acute illness, including fever and thrombocytopenia associated with high levels of virus 
replication. Resolution of the acute stage of disease is associated with the appearance of 
virus-specific cytotoxic T-lymphocyte (CTL) response, and a decrease in the level of plasma 
viremia (15, 26). In the chronic stage which follows, recurrent episodes of high titer viremia 
and associated disease are observed within the first year following infection, and usually 
abate in frequency and severity over time. Most horses then enter an inapparent stage, 
exhibiting no signs of disease, yet are unable to clear the virus, remaining inapparent carriers 
of the virus for life (16, 21, 23, 29, 33). 
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We and others have observed genetic variation in the region of the EIA V genome 
where the second exon of Rev overlaps the cytoplasmic tail of the transmembrane protein (2, 
6, 23). Rev is a regulatory protein that controls nuclear export of unspliced and single 
spliced viral mRNAs, which are essential to virus replication. Therefore, factors that 
modulate Rev activity, and consequently, alter levels of viral gene expression may be 
important in regulating virus replication in vivo. To examine this possibility, we recently 
undertook a comprehensive longitudinal analysis of genetic and biological variation in Rev 
throughout a clinically dynamic disease course in one pony experimentally infected with the 
virulent EIAVwyo207s (5). The pony exhibited multiple fever cycles during the first four 
months of infection, and the onset of the inapparent stage of disease was associated with the 
appearance of detectable neutralizing antibody. Phylogenetic and partitioning analyses 
identified multiple subpopulations of the EIA V Rev quasispecies (4). These subpopulations 
coexisted during disease, evolved differently, and differed in phenotype. Moreover, these 
subpopulations fluctuated in dominance in a manner coincident with disease state. The 
subpopulation dominant in the chronic and late chronic stages of disease exhibited a high 
Rev phenotype, whereas the subpopulation dominant in the inapparent stage of disease 
exhibited low Rev phenotype. 
In the present study, we used genetic and biological tools to characterize the Rev 
quasispecies of another EIA V-infected pony. This pony was a short term progressor, 
experiencing severe recurring episodes of clinical disease, and did not survive past the 
chronic stage of disease. Results identified two subpopulations which coexisted, differed in 
phenotype, and had similar patterns of evolution. A quasispecies comprised of multiple 
subpopulations that occupy different regions on a fitness landscape could allow a virus to 
adapt rapidly to changes in the host environment by expanding minor, less fit subpopulations 
that may be near the new fitness peaks. Such a model may provide new insight into the 
factors that shape the evolution of viral quasispecies during progression of disease. 
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MATERIALS AND METHODS 
Experimental infections and identification of Rev variants. Pony 625 was 
inoculated intravenously with 2 mL of heparinized plasma collected from pony 524 at 878 
days post infection. The virulent Wyoming strain of EIA V was used to infect pony 524, as 
previously described (5). Viral RNA isolated from the inoculum and from sera collected 
during variable stages of disease was reverse transcribed and amplified with primers to 
conserved regions of EIA V (Fig. 1 ). PCR amplification conditions consisted of 3 7 cycles of 
denaturation at 94°C for 2 min, annealing at 50°C for 1 min, and extension at 72°C for 1 min. 
The initial and final cycles contained a prolonged extension at 72°C for 5 min. Then 2 µL of 
PCR product was cloned into pGEM-T vectors as recommended by the manufacturer 
(Promega, Madison, WI) and transformed into Escherichia coli DH5a. Clones were 
sequenced bidirectionally with primers to vector sequences flanking the insert. Sequencing 
was performed by the Iowa State University DNA Synthesis and Sequencing Facility with an 
automated DNA sequencer. Sequences were aligned by MacVector and AssemblyLIGN 
software (Oxford Molecular, Beaverton, OR). 
Sixteen clones were analyzed from the pony 625 inoculum and 13 to 21 clones from 
each of five sequential serum samples collected at 14, 25, 46, 67, 77 days post infection. Rev 
amino acid variants were named in the order they were identified, with identical variants 
given the same name. The names for pony 625 Rev variants were continued from the 
numbering of pony 524 variants. 
Analysis of Rev quasispecies. Phylogenetic analyses were used to characterize the 
genetic relationship among variants in pony 625. The neighbor-joining distance method 
based on p-distance was used to construct unrooted phylogenetic trees from the Rev amino 
acid sequences with MEGA vs. 2.1 (22) . Other methods for estimating amino acid 
substitutions between clones, i.e., number of amino acid differences, Poisson-corrected 
distance, and gamma distance, were also used, and resulted in trees nearly identical to those 
presented in this paper. Bootstraps were calculated over 1000 repetitions. 
The program P AQ, for partition analysis of quasispecies, was used to group the rev 
genotypes that were most similar at each time point (3). The program uses the Hamming 
distance as a measure of distance between rev variants and a nonhierarchical clustering 
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method to identify discrete and cohesive partitions of closely related sequences, similar to 
other clustering algorithms (24). However, PAQ does not select a predetermined number of 
partitions, and overlap between partitions is allowed. The optimal output maximizes the 
number of variants contained within the partition while minimizing the partition radius and 
any overlap between partitions. The central genotype of each group is the sequence most 
representative of all variants within the group. A standard comparison of two population 
means was used to determine whether distances within each group were statistically different 
from distances between two groups. A z-statistic, assuming a normal distribution, was 
calculated with the mean and variance of the two populations and tested under the criterion 
of p < 0.01. 
Construction of Rev expression plasmids and CAT assays. Selected Rev variants 
were subcloned into a Rev expression vector and assayed for nuclear export activity as 
previously described (6). pERevWT, which was previously described as pcH21, contains 
Rev cDNA in the pCR3 background (5) (Invitrogen, Carlsbad, CA). The rev exon 2 was 
removed by digestion with the restriction endonuclease ApaI. The digested plasmid was gel 
purified, dephosphorylated, and ligated with the exon 2 sequence of rev variants as described 
( 5). All clones were confirmed by sequencing. 
Rev dependent nuclear export activity was determined in transient transfection assays 
with the pERRE-All reporter plasmid, a derivative of pDM138 with an intron containing the 
chloramphenicol acetyltransferase gene and EIA V nucleotides 5280 to 7534 (6). 293T cells 
were transfected with 1 µg of either pcDNA3 or Rev variant plasmid, 0.2 µg of pERRE-All 
reporter plasmid, 0.2 µg ofpCHl 10 (Amersham Pharmacia Biotech, Piscataway, NJ), and 
0.6 µg of pUC19. Two days posttransfection, cells were harvested, resuspended in 0.5 mL of 
0.25 M Tris (pH 7.5), lysed by freeze/thawing, and assayed for ,8-galactosidase activity to 
normalize CAT assays for transfection efficiency. Normalized lysates were assayed for CAT 
activity using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Roche, 
Indianapolis, IN). Experiments were performed in triplicate, and results summarize nine 
transfections. Statistical significance was determined by analysis of variance. 
Nucleotide sequence accession numbers. GenBank accession numbers are 
AF512608 to AF512669. 
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RESULTS 
Rev quasispecies of Pony 625. Pony 625 underwent several febrile cycles over the 
acute and chronic stages of disease, became moribund, and was euthanized at 89 days post 
infection (Fig. 2). Viral RNA was isolated from the inoculum and from serum samples 
collected at sequential times post infection. Sequence analysis identified a heterogeneous 
population of Rev variants in the inoculum and throughout infection (Fig. 3). Further 
examination of the quasispecies structure, showed the predominant sequence at every time 
point examined was R93, a variant that was predominant in pony 524 late in infection (5). A 
minor group ofrelated sequences, represented by Rl 03, was also present in the inoculum and 
most time points examined (except 14 days post infection). R103 differed from R93 at eight 
amino acid positions, but only differed by two amino acids from Rl, the dominant variant of 
Pony 524, which was not observed in pony 625. 
Subpopulations identified in Rev quasispecies of pony 625. Phylogenetic analysis 
of pony 625 variants identified two major clades, designated clade A and clade B (Fig. 4A). 
Clade A included R93 like variants, and clade B included Rl03 and its related variants. The 
variation between these two clades of pony 625 Rev variants was more distinct than the 
separation observed in pony 524, supported by bootstraps of 82%. When the entire data set 
of 524 and 625 variants were analyzed together, pony 625 clade A variants grouped with 
pony 524 clade A variants, and pony 625 clade B variants grouped with pony 524 clade B 
variants (Fig. 4B). Thus the subpopulations of Rev showed greater similarity between 
ponies, rather than within ponies. 
Subpopulations of pony 625 coexist in vivo. Each time point sampled contained 
Rev variants from both subpopulations, with the exception of dpi 14. To more clearly 
characterize the temporal relationship between the two sub-populations, we used a computer 
program, partition analysis of quasispecies (P AQ), to detect natural partitions, or groups, of 
nucleotide variants at each time point (3). This program uses the Hamming distance as a 
measure of distance between rev/tm genotypes, and employs a nonhierarchical clustering 
method to define groupings of variants, represented graphically as circles. Each group 
contains a central genotype, which is the most representative of all other variants within the 
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group. Application of P AQ to the pony 625 dataset indicated most time points could be 
partitioned into two groups of genotypes, each with a radius of three nucleotide changes or 
less (Fig. 5). Statistical analysis confirmed that the mean distance among variants within a 
group was significantly smaller than the mean distance among variants between groups (p < 
0.01). In pony 625, as with the similar analysis of pony 524, there was 90 to 100% 
correlation between the partition grouping and the phylogenetic grouping of the variants. In 
contrast to pony 524, dynamic changes in predominance between the two groups were not 
observed in pony 625. This may be due, in part, to the fact that the clinical disease course in 
pony 625 did not progress beyond the chronic stage of disease. Despite these differences, the 
P AQ analysis of pony 625 variants clearly demonstrated that minor subpopulations of rev/tm 
quasispecies can persist in EIA V infected horses. 
Subpopulations of Rev differ in phenotype. The phylogenetic and partition 
analyses identified two subpopulations of Rev variants that appeared to coexist and differ in 
selective advantage. To determine whether there were phenotypic differences between the 
two Rev subpopulations we used a chloramphenicol acetyltransferase (CAT) reporter system 
to quantitate the nuclear export activity of the central genotype from each of the partitions as 
well as representative variants from the phylogenetic trees. Three variants, R93, R102, and 
R103, representing 54% of the Rev quasispecies of this pony were tested for Rev phenotype. 
For each variant, CAT activity was normalized to the activity level ofRl, the founder variant 
in pony 524 (5). Results are reported as Rev activity relative to Rl, and shown with the 
variants phenotyped from pony 524 (Fig. 6). The variants tested from pony 625 sorted by 
subpopulation, as seen in pony 524. Furthermore, Rev activity of all variants from 
subpopulation A was significantly higher than the activity of Rev variants of subpopulation B 
(p < 0.0001). 
DISCUSSION 
These studies provide further experimental evidence that a viral quasispecies may 
comprise multiple subpopulations that evolve independently and possess distinct selective 
advantages. Phylogenetic analysis of the Rev quasispecies in a pony experimentally infected 
with EIA V identified two subpopulations of variants that differed in their genetic divergence 
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and pattern of evolution. Multiple subpopulations of Rev variants were also detectable with 
partition analyses, which showed that the subpopulations coexisted in vivo. Transient 
expression assays demonstrated that the two subpopulations differed in Rev-dependent 
nuclear export activity. This was in agreement with previous results of multiple 
subpopulations which coexisted and fluctuated in a manner coincident with disease stage in 
another EIA V-infected pony (4). Subpopulations that differ in phenotype would be predicted 
to occupy different regions on the fitness landscape and rapidly respond to changes in the 
landscape topology. Such a model may provide additional insight as to how viruses adapt so 
quickly to changes in the host environment. 
Several studies have reported the presence of genetically distinct populations ofHIV-
1 in different infected organs and even in different regions within the same organ (1, 32-35). 
Anatomical sequestration of virus populations may provide a biological niche that could lead 
to the subdivision of the quasispecies into smaller, semi-isolated groups that differ in 
phenotype and/or selective advantage. For example, the differential expression ofHIV-1 
coreceptors on CD4+ subsets was associated with the coexistence and independent evolution 
ofHIV-1 viruses that differed in syncytium-inducing phenotype (33). Our analyses of the 
evolution of Rev quasispecies during progression of EIA disease included over 400 revltm 
sequences from two experimentally infected ponies and the genetic variation within the entire 
data set of revltm variants was relatively low, each of the genotypic and phenotypic assays 
pointed to the same conclusion: two coexisting subpopulations within the Rev quasispecies 
that differed not only genetically but also phenotypically. Furthermore, the changes in 
population size coincided with disease state, even in pony 625 which did not progress past 
the chronic stage of disease. The afebrile time point sampled within the chronic stage 
showed growth of the minor subpopulation. Together, these data strongly suggest the 
presence of subpopulations of Rev that occupied distinct biological niches, which differed in 
selective advantage during progression of disease. 
Genotypes representative of the two subpopulations of Rev quasispecies exhibited 
significant differences in biological assays. The chronic stage of disease was predominated 
by variants with higher Rev activity, as we had observed before. The afebrile time point 
sampled within the chronic stage of disease showed a marked growth in the minor 
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subpopulation in pony 625. These findings agree with the statistical analyses of quasispecies 
Rev activity in pony 524, which showed that the clinical stages of EIA V infection were 
correlated with Rev activity (5). The fact that similar conclusions were reached via different 
computational and genetic approaches in two EIA V-infected horses supports the hypothesis 
that Rev phenotype contributes to variant selection in vivo. Interestingly, in pony 625, the 
two subpopulations did not show a linear evolution reflecting the accumulation and fixation 
of mutations, as observed in subpopulation A of pony 524. However, differences in selective 
pressures and correlation with disease progression within these two hosts are unknown. 
Recent studies by Bobbitt et al. (7), demonstrated that variation in HIV-1 Rev activity 
can alter sensitivity to CTL killing by downmodulating viral late gene expression. A single 
amino acid substitution in HIV-1 Rev resulted in a two- to three-fold reduction in Gag 
expression and a significant decrease in CTL killing. Furthermore, primary HIV-1 isolates 
from asymptomatic patients showed reduced Rev activity, reduced levels of Gag expression, 
and increased resistance to CTL killing. Similar to our results, these findings indicate that 
limited amino acid changes in Rev can attenuate activity and may confer a selective 
advantage in vivo. Recent studies by Mealey et al. (27), have shown that EIA V-infected 
horses which show minimal disease, nonprogressors, exhibited high to moderate avidity 
memory CTL directed against epitopes within Rev, whereas these were not found in 
progressors. Also, in HIV-1 infected patients, long term progressors exhibited a broad 
persistent immunological response and a greater number of sites exhibiting positive selection 
persisted over time, whereas short term progressors exhibited narrow, shifting immunological 
response and had fewer and less persistent positively selected sites (31 ). While changes in 
the cytoplasmic region of TM and/or changes in cytotoxic T-cell epitopes may also 
contribute to variant selection, it is reasonable to hypothesize that attenuation of Rev activity 
may be advantageous for viral persistence in the presence of a significant host immune 
response. Ongoing studies in additional EIA V-infected horses will increase our 
understanding of the role of Rev variation in immune evasion and viral persistence. 
The coexistence of multiple subpopulations within a viral quasispecies implies the 
persistence of minor subpopulations of viral variants that have reduced fitness relative to 
variants in the predominant population. This impacts our understanding of how virus 
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populations evolve and how their evolution may be modeled. Multiple coexisting 
subpopulations that differ in selective advantage would occupy different regions on a fitness 
landscape and would allow the virus to adapt rapidly to changes in the host environment by 
expanding minor populations that may be near new fitness peaks. This may be especially 
relevant in modeling reservoirs of persistent replicating virus and the emergence of virus 
variants. For example, failure of antiviral drug therapy can arise from de novo generation of 
resistant variants due to incomplete suppression of replicating virus or from selection of a 
minor pool of existing resistant variants. 
In a quasispecies model where there is only one population of variants, existing 
resistant variants are rare, and drug resistance would result from the accumulation and 
fixation of mutations that reduce susceptibility to therapy. In a model with multiple 
subpopulations, an existing minor pool of less fit genotypes may include resistant variants 
that require fewer point mutations to confer drug resistance. In this model, the changes in 
fitness landscape following the onset of antiretroviral therapy would induce rapid expansion 
of the minor subpopulation ofresistant variants and persistence of drug-sensitive variants as 
the minor population. The latter model may help explain the rapid rebound of wild-type 
virus observed in some HIV-1 patients undergoing structured treatment interruptions (8, 9, 
11, 30). Further examination of the genetic and phenotypic complexity of virus populations 
in vivo will aid our understanding of quasispecies structure and lentiviral evolution. 
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FIG. 2. Febrile response of pony 625 following experimental infection. The temperature 
was measured daily during clinical episodes and intermittently during chronic clinical 
disease. Febrile episodes (defined as 100°F or higher) are shown. Days at which serum 
samples were collected are on shown on the X-axis. 
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FIG. 3. Frequency and alignment of Rev amino acid (a.a.) sequences obtained from the pony 
625 inoculum and sequential sera samples. The frequency (N) and variant identity (V) are 
given for each time point, and the total number of clones sequenced is indicated below the N 
column. Sequences are compared to R93, which is the dominant variant in the pony 625 
inoculum. For individual sequences, (.) indicates an a.a. identical to R93 at that position,(*) 
indicates a premature stop codon in the rev ORF, and(+) indicates a frameshift. 
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CladeA 
Clade A 
I CladeB Clade B 
I CladeC 
FIG. 4. Phylogenetic analysis of Rev variants. (A) Neighbor-joining tree of the pony 625 
Rev amino acid variants based on p distance. The tree is divided into 2 clades, designated 
Clades A and Clade B. The Rev variants highlighted by yellow boxes were biologically 
assayed for Rev activity. (B) Neighbor-joining tree of the combined pony 524 and pony 625 
Rev amino acid variants based on p-distance. Solid lines indicate pony 524 variants and 
dashed lines indicate pony 625 variants. 
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lnoculum 
Acute Chronic 
FIG. 5. Partition analysis identifies two co-existing sub-populations of rev variants in pony 
625. The groups present at each time point were found using the program PAQ. The relative 
size of each group represents the proportion of the population contained within the group at 
that time point. The central Rev variant for each group is shown, and the arrows show from 
which group the central variant likely evolved. Variants within the same group were 
generally found within the same clade of the phylogenetic trees (shown in Fig. 4) and the 
color of the group corresponds to the clade from which most variants were found. The 
different groups were designated Group 1 (red), and Group 2 (blue). The day post-infection 
and clinical stage of disease are indicated. 
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Rev Variant 
FIG. 6. Sub-populations of Rev differ in phenotype. Nuclear export activity of pony 524 
variants (solid bars) and pony 625 variants (striped bars) are reported relative to the activity 
of Rl . Results represent the mean activity of at least 9 independent transfections ± SEM. 
Variants that differed significantly from the activity ofRl are indicated, with p-values 
represented by(*) p<0.05, (**) p<0.005, and(***) p<0.00005. 
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CHAPTER 4. GENERAL CONCLUSIONS 
Lentiviruses cause lifelong persistent infections, and some, such as HIV, SIV and 
feline immunodeficiency virus (FIV), result in suppression of the immune system and death 
from opportunistic infection. In contrast, EIA V may cause a variable disease course with a 
rapid onset, followed by progression into an inapparent stage of disease. Continual viral 
replication is observed throughout the inapparent stage, yet at low levels, indicating the host 
has achieved some level of immunological control of the virus (2, 8). HIV is constantly 
evolving, even in patients on strict antiretroviral therapy, which controls viral replication, and 
cessation of drug therapy results in rapid rebound of the virus (4, 5, 7, 11). Likewise, EIAV 
continues to evolve throughout the inapparent stage of disease, and recurrence of chronic 
disease can occur (2, 9). We have taken advantage of the EIA V model to further our 
understanding of the mechanisms of lentiviral variation and persistence. Specifically, we 
have examined the quasispecies of a regulatory protein critical to viral replication, known to 
exhibit variation, throughout the course of disease in two horses experimentally infected with 
EIAV. Multiple subpopulations of EIAV Rev were identified, and these studies 
characterized the genotypic and phenotypic differences within and between subpopulations. 
EIAV REV VARIATION THROUGHOUT DISEASE PROGRESSION 
Len ti viruses exist in vivo as a population of highly related variants, termed a 
quasi species. This variation is due to the combination of several inherent properties of 
lentiviruses, namely, a high replication rate, small genome size, and a high mutation rate. 
The variation observed in the quasispecies throughout disease, however, is the result of many 
evolutionary mechanisms acting on the virus, including natural selection, genetic drift, 
recombination, migration, compartmentalization, and persisting minority subpopulations. To 
study Rev variation throughout disease, we undertook a comprehensive longitudinal analysis 
of Rev variation in two horses experimentally infected with EIAV. In both EIA V-infected 
horses, Rev exhibited a quasispecies distribution marked by genotypically and 
phenotypically distinct variants (1, 2). Moreover, in both horses, the EIAV quasispecies was 
composed of multiple subpopulations ( 1 ). These subpopulations were phenotypically 
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distinct, and correlated with clinical stage of disease; high Rev activity subpopulations 
associated with chronic stages of disease, and low Rev activity subpopulations with the 
inapparent and afebrile stages of disease. 
SELECTION ON REV 
Genetic Analyses. Genetic analyses indicated that Rev, as a whole, was under 
purifying selection. Only nine amino acid positions differed from the founder sequence of 
the inoculum at a frequency greater than 0.10 in pony 524. Rev is a critical regulatory 
protein, key to the persistence of the virus, both in controlling viral replication, and 
contributing to immune evasion by down-regulating the expression of viral genes. So, it is 
not surprising that 70 of 135 amino acids in Rev were 100% conserved, and 121 positions 
varied by less than two percent. Conserved sites included most of the defined functional 
domains, the NES, NLS, and a region known to be essential to Rev function. Quasispecies 
theory predicts most mutations would be deleterious and therefore selected against. This is 
supported by the fact that we observed mutations at 65 positions, yet we see fixation of 
amino acid mutations at only ten of these, and in most cases only one amino acid mutation 
per position. This region of the EIA V genome has even greater constraints, in that it 
encompasses an overlapping reading frame with the transmembrane protein. This increases 
the likelihood of a nucleotide change to cause nonsynonymous change in one or both reading 
frames. Each of the nine positions showing non-synonymous change in rev also caused 
nonsynonymous change in tm. This is consistent with studies of the selective pressures on 
HIV genes; a small proportion of positively selected sites have been identified within all nine 
HIV genes, even those under purifying selection (6). 
Phenotypic Analyses. The sensitivity of Rev to variation is further demonstrated by 
the phenotypic analyses, which showed Rev activity is extremely sensitive to single amino 
acid changes. This study shows the effect of the high frequency mutations in pony 524 on 
Rev activity both singly in the context of the consensus sequence of the inoculum, variant 
Rl, as well as in the context of other mutations, as observed in vivo. Our study shows the 
fixation of a single amino acid mutation can result in significant increases and decreases in 
Rev activity. Interestingly, the ability of the amino acid mutations to affect Rev phenotype 
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was highly dependent upon the context of other amino acid mutations already present in the 
variant. This is best illustrated by the mutation G 11 OD. This mutation, singly in the 
backbone ofRl, caused the greatest increase in phenotype relative to Rl. When observed in 
the context of three mutations fixed into subpopulation A over time, however, it had no effect 
on phenotype relative to the preceding mutant. Likewise, the fixation of V 105A, had no 
effect on phenotype in the context of the Rl backbone, yet resulted in a significant increase 
in activity when in the context of other mutations. This illustrates the need to evaluate 
mutations in the context observed in vivo. 
CHARACTERIZATION WITHIN AN~ BETWEEN SUBPOPULATIONS OF EIAV 
REV 
Our understanding of the role of minor subpopulations on viral persistence is just in 
its infancy. These studies provide further experimental evidence of viral subpopulations 
which differ in phenotype and evolve under different selective pressures. Genotypic and 
phenotypic analysis of two previously identified subpopulations of the Rev quasispecies from 
an EIA V-infected pony identified only ten high frequency amino acid mutations fixed into 
the quasispecies over time. These mutations defined these subpopulations, and could 
significantly alter Rev phenotype. 
Variation within subpopulations. Interestingly, nine of the ten mutations were 
fixed only into subpopulation A, associated with high Rev activity. These mutations became 
a part of the dominant genotype of this subpopulation. The fixation of these mutations 
throughout disease, however, did not confer increasing Rev activity, rather, maintained a Rev 
activity similar to that of the mutant containing the first mutation fixed into the population. 
Subpopulation B, associated with low Rev activity, exhibited a very different evolution 
throughout disease. Only one mutation was fixed into this subpopulation, and this mutation, 
which significantly increased Rev activity, never became a part of the dominant genotype of 
this subpopulation. In fact, the founder variant, Rl was the dominant genotype of this 
subpopulation at every time point sampled. The phenotypic variation within subpopulations 
resulting from the fixation of these ten high frequency mutations was similar in range, if not 
in dominance. 
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Variation between subpopulations. The greatest difference in phenotype was 
observed between the two subpopulations. Intriguingly, the largest phenotypic difference 
between subpopulations, resulting from the fixation of a single amino acid, was observed 
with the fixation of the first amino acid mutation from the inoculum. This is consistent with 
studies of viral fitness in which the largest fitness gain, associated with the accumulation and 
fixation of mutations, occurs early (10). This also supports the idea that coexisting multiple 
subpopulations provide an advantage to the virus in that they occupy distinct niches on a 
fitness landscape (1, 3). Quasispecies shifts, or expansion of a minority subpopulation near 
the new fitness peak, would allow the virus to more rapidly adapt to changes in its 
environment, as opposed to evolving toward the new fitness peak through the accumulation 
and fixation of point mutations. 
REV PHENOTYPE AND CLINICAL DISEASE 
In the case of EIA V, selection of the dominant Rev subpopulation is correlated with 
Rev phenotype and disease. The high Rev phenotype subpopulation is dominant in the 
chronic stages of disease, when viral replication is high, and the low Rev phenotype is 
dominant in the inapparent stage of disease, when viral replication is low. It is interesting to 
note that in HIV, mutations which confer drug resistance are often associated with lowered 
replication rates (3). In a patient undergoing drug therapy, this variant is more fit than the 
wild type variant, with high replication, yet both exist as majority and minority 
subpopulations, respectively. Following interruption of drug therapy, rapid rebound of the 
wild type minority subpopulation is observed, but the drug resistant subpopulation is 
maintained, becoming the minority population. In EIAV, the low Rev phenotype 
subpopulation is associated with lower viral replication. This may allow the virus to evade 
the immune system and to persist in the host. Unknown changes in pony 524 resulted in a 
quasispecies shift late in the course of disease, with the high activity subpopulation became 
dominant once again, but minority subpopulations persisted. 
Also of note, was the difference in the diversity within subpopulations between the 
two EIAV-infected horses. Pony 524, a long term progressor, exhibited recurrent disease 
and eventually entered an inapparent stage of disease, whereas pony 625 was a short term 
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progressor, exhibited severe acute disease, became moribund, and was euthanized. The 
subpopulations identified in pony 625, however, were more homogeneous than those 
observed in pony 524, and exhibited fewer mutations fixed into the population. This is 
consistent with studies of the envelope protein in HIV patients, in which long term 
progressors exhibited viral populations which diverged faster, and showed signs of a broad 
immune response, while short term progressors had more homogeneous populations, fewer 
selected sites, and showed signs of a narrow shifting antibody response (12, 13). 
As well as being highly sensitive to single amino acid changes, the dominant in vivo 
EIAV Rev variants of pony 524 exhibited a limited range of Rev activity. The phenotypic 
range for the dominant and recurring variants from pony 524 was 63% to 221 %, relative to 
the founder variant, Rl at 100% (2). Variants near the limits of this range were observed 
transiently, and were never the dominant genotype of the quasispecies. This may suggest 
biological bounds of Rev activity, and guide selection accordingly. Variants with too great a 
Rev phenotype will be selected against, as will variants with extremely low Rev activity. 
Rev autoregulates its own production, and if it performs its job too well, theoretically, it 
would select against the genotype that produced the high Rev phenotype. Likewise, Rev 
variants with low Rev phenotype, may not replicate fast enough to compete with other viral 
variants. The accumulation and fixation of the high frequency mutations in subpopulation A 
of pony 524 did not select for higher and higher Rev phenotype. In fact, of the three mutants 
that exhibited Rev activity greater than 200%, only one was observed in vivo without any 
other mutations. The Rev quasispecies appeared to quickly fix compensatory mutations 
which lowered the Rev activity to levels below 200%. This was independent of whether the 
subpopulation was dominant or not. Interestingly, we observe variants with phenotype over 
200% only during the chronic stage of disease and as a possible ancestral sequence prior to 
the late chronic stage of disease. 
FUTURE STUDIES 
The results of the characterization within and between subpopulations of EIAV Rev 
throughout the course of disease in this study validate the role of multiple subpopulations 
throughout disease. However, these studies indicate the need for further studies to 
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understand how the selection within and between subpopulations relates to progression of 
disease and viral persistence. The present study characterized EIA V Rev quasispecies 
evolution in the context of two EIA V-infected horses. Further understanding will be gained 
through the examination of more infected horses, which exhibit both similar and different 
disease progression. More in depth sampling throughout the course of infection will also 
provide better understanding of the changes occurring throughout disease. The 
characterization of variation within other genes, and covariation with EIA V Rev and clinical 
disease, will greatly enhance our understanding as well. Further examination of the role of 
Rev in immune evasion, and as a target of the immune system is warranted. Characterizing 
the evolution of the entire virus throughout disease would be of great value in establishing 
selection on the entire virus, and provide insight into quasispecies evolution and lentiviral 
persistence. 
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